It is a high-performance vaccine, a new type of vaccine that does not include any portion of germs as such. It does not contain fractions of virus or whole virus killed or attenuated virus, as all vaccines were now. It is a vaccine that contains the “genetic prescription” of the antigen that our body will then produce, as an antigen, and against which our whole body will produce antibodies in the form of this recipe. When the body comes in contact with the real virus, the antibodies are ready.
Scientists say it reduces the risk of side effects because it does not contain virus fragments, as is the case with other types of conventional vaccines.
It simply came to our notice then. It is an extremely new and extremely effective vaccine from a medical point of view and as a vaccine preparation technology. It is absolutely recommended.
Two of the vaccines have now reached the level of general administration, so they have an opinion, they are prepared according to the same style, they have the same platform.
These sera must be stored and transported under special conditions.
Temperatures of minus many degrees for one and minus fewer degrees for the other. In any case, a very rigorous cold chain must be maintained for both, because the only potential weak point is that it is not stable enough at normal temperatures.
Fears about the presence of dangerous or untested substances in these vaccines are unfounded and explain how they are approved.
These vaccines are extremely well-studied substances. There are whole batches, for example for this Sars-CoV-2 vaccine there were about 50,000 people tested in official clinical trials, as they are done worldwide.
A vaccine is never given on the market until the concept of safety, tolerability, and efficacy profile is safe.
If during clinical trials, no matter what they are, with a drug, with a vaccine, a patient suffers something, something that clearly has nothing to do with that substance, for example, if he hits a car on him on pedestrian crossing while in this clinical trial is considered a severe adverse effect of the trial. They think, “Did the car hit him because he was dizzy from the substance?” Until this is clarified, the trial is stopped. Things are taken very seriously. Nothing is ever left to chance and, in addition, after a vaccine is placed on the market for use, it is still followed, post-marketing, with warnings and communications of side effects and others, for a few more years, to prevent any other things that were not noticed in a timely manner. But this is extremely rare, something else to happen.
How the flu vaccine can benefit from the new Covid-19 vaccination technology
For scientists studying influenza viruses, the latest scientific discoveries in the field are very important, because they announce an acceleration of their research – Source Bloomerang.
“We’ll see how vaccines and all these new technologies work,” said Gregory Glenn, research director at Novavax, who works on Covid and flu vaccines.
Influenza viruses that infect humans are constantly changing, so twice a year – around the peak of the flu seasons in the winters of the northern and southern hemispheres – the WHO is working on the best estimate of the strains that could appear the following year. Pharmaceutical companies use this information to develop vaccines and start production as soon as possible, usually by injecting viruses into hundreds of millions of hens’ eggs, where they grow for several days before being extracted. After a few weeks of additional processing, by the end of the summer, the manufacturers send the anti-influenza sera to clinics and pharmacies for distribution to patients during the autumn.
In some years the procedure works quite well, in other times the performance is abysmal. Vaccines have been between 10% and 60% effective in the last 15 years, according to US infectious disease expert Anthony Fauci. “Once vaccine production begins, it is almost impossible to start a new one if a different viral strain appears,” Fauci told Congress last year.
Some techniques explored by Covid researchers are fundamentally different. Instead of viral proteins, Pfizer-BioNTech and Moderna vaccines contain so-called messenger RNA, or mRNA – the genetic instructions that cause the body to produce disease-specific antigens, effectively transforming itself into its own vaccine factory. The technology is still new, and a successful debut against Covid would boost public confidence in mRNA vaccines for influenza and other diseases, according to Meagan Fitzpatrick, an assistant professor at the University of Maryland School of Medicine. “It will be a huge boost. The biggest obstacles will already be overcome, “she said.
The second flu technology ready to take advantage of Covid research is the so-called recombinant vaccine, an idea pursued by Novavax and Sanofi. In this process, scientists removed from the DNA of the virus what triggers an immune response. Technicians combine DNA with genetic material that can penetrate insect cells such as moths, which successfully grow proteins and are easy to grow. The cells then produce the antigen that can be harvested for use in the vaccine. A Sanofi subsidiary signed a $ 226 million contract in December last year with the US State Department of Health and Human Services to increase production capacity for recombinant flu vaccines at a facility in Pennsylvania.
Although not used in Covid research, so-called vaccines that use cell cultures – which avoid the use of eggs – benefit from this interest. In this approach, the virus grows in cells of mammalian origin, which are preferable because the virus no longer seeks to adapt to its avian host.
However, a renewed focus on influenza and the money being spent on Covid prevention will speed up the transition from eggs to new technologies that are becoming more acceptable, says Leo Poon, head of the Department of Public Health Laboratory Sciences at Hong University. Kong. “It will certainly help develop more effective vaccines for other diseases,” he says.
Pfizer, BioNTech, and Moderna, which do not currently offer influenza sera, are already applying mRNA vaccines to others in addition to Covid. The technology “will change the flu market,” said Mikael Dolsten, Pfizer’s scientific director. “We see a great opportunity.”